Targeting the Gut to Modify Parkinson’s Disease: From Mechanisms to Potential Therapeutics
Journal of Movement Disorders · 31.10.2026 · 19 (4) · 365-383
DOI: 10.14802/jmd.26285 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Movement Disorders, erschienen am 31.10.2026. Verfasst von Yi-Cheng Tai und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, E-DA Hospital, I-Shou University, Kaohsiung, Taiwan. Die Arbeit nennt 176 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Taiwan University Hospital, E-Da Hospital.
Abstract (Originalsprache)
Parkinson’s disease (PD) is the second most common neurodegenerative disorder and its prevalence continues to rise with population aging. Its cardinal motor features arise from the loss of dopaminergic neurons in the substantia nigra, accompanied by intraneuronal α-synuclein aggregates known as Lewy bodies. Neuropathological evidence suggests that, in a subset of patients, α-synuclein pathology first appears in the enteric nervous system and ascends to the brain via the gut–brain axis. Consistent with this “body-first” trajectory, a growing body of work has documented distinct alterations in gut microbial composition and microbiota-derived metabolites in people with PD relative to healthy individuals, with some changes detectable in the prodromal phase. Current management, whether dopaminergic pharmacotherapy or deep brain stimulation, alleviates motor symptoms but does not slow neurodegeneration, and long-term treatment is complicated by motor fluctuations and other adverse effects. Therapies directed at the underlying disease process are therefore urgently needed. Because early perturbations of the gut microenvironment appear to contribute to PD pathogenesis, interventions that restore gut homeostasis represent a rational disease-modifying strategy, particularly for patients whose pathology originates in the gut. This review synthesizes current understanding of how the gut microbiota shapes the gut–brain axis in PD, spanning immune, metabolic, neuroendocrine, and neural pathways, and critically appraises the emerging evidence for microbiota-directed interventions, including fecal microbiota transplantation, probiotics, and prebiotics, as candidate disease-modifying therapies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology, E-DA Hospital, I-Shou University, Kaohsiung, Taiwan.
- School of Medicine, I-Shou University, Kaohsiung, Taiwan.
- Department of Neurology, National Taiwan University Hospital, Taipei, Taiwan. chlin@ntu.edu.tw.
- Graduate Institute of Biomedical Engineering, College of Medical Science and Technology, National Taiwan University, Taipei, Taiwan. chlin@ntu.edu.tw.
- Graduate Institute of Molecular Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan. chlin@ntu.edu.tw.
- Graduate Institute of Brain and Mind Sciences, College of Medicine, National Taiwan University, Taipei, Taiwan. chlin@ntu.edu.tw.
Förderung
- National Taiwan University Hospital
- E-Da Hospital
Zitieren
APA
Tai, Y. C., & Lin, C. H. (2026). Targeting the Gut to Modify Parkinson’s Disease: From Mechanisms to Potential Therapeutics. Journal of Movement Disorders, 19(4), 365-383. https://doi.org/10.14802/jmd.26285
Vancouver
Tai YC, Lin CH. Targeting the Gut to Modify Parkinson’s Disease: From Mechanisms to Potential Therapeutics. Journal of Movement Disorders. 2026;19(4):365-383. doi:10.14802/jmd.26285
BibTeX
@article{Tai2026,
author = {Tai, Yi-Cheng and Lin, Chin-Hsien},
title = {Targeting the Gut to Modify Parkinson’s Disease: From Mechanisms to Potential Therapeutics},
journal = {Journal of Movement Disorders},
year = {2026},
volume = {19},
number = {4},
pages = {365--383},
doi = {10.14802/jmd.26285}
}
EUVIMED